Pharma2b

C. Warren Olanow MD, Karl Kieburtz MD, Mika Leinonen MSc, Lawrence Elmer MD, Nir Giladi MD, Robert A. Hauser MD, Olga S. Klepiskaya MD, David L. Kreitzman MD, Mark F. Lew MD, David S. Russell MD, Shaul Kadosh MSc, Pninit Litman PhD, Hadas Friedman MSc, Nurit Linvah PhD Published: 3 April 2017 Journal Movement Disorders DOI: 10.1002/mds.26941 … Read more

REHOVOTH, Israel, February 27, 2017 — Pharma Two B Ltd., a privately held biopharmaceutical company focused on developing treatments for Parkinson’s disease, announced today it has completed its third round of financing. The $30MM funding round was led by Israel Biotech Fund (IBF) which identified the company, led the due diligence, and syndicated with leading … Read more

Rehovoth, Israel, June 30, 2015 — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company’s Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson’s Disease (PD). P2B001 is a combination of low dose pramipexole and low … Read more

Rehovoth, Israel, June 30, 2015 — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company’s Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson’s Disease (PD). P2B001 is a combination of low dose pramipexole and low … Read more

Published in Scrip Magazine by Donna Young, April 22nd 2011 Israeli start-up Pharma Two B has taken the concept of synergism seriously, from the eclectic group of scientists and managers it has brought together under one roof, to its fixed-dose combination strategy of drug development, to the approval pathway it plans to seek in gaining … Read more